Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer.
Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation. Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL's relationship to survival.